Xeris Biopharma (XERS) to Release Earnings on Friday

Xeris Biopharma (NASDAQ:XERS) will post its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect Xeris Biopharma to post earnings of ($0.09) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, August 8th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. Xeris Biopharma had a negative return on equity of 16,662.63% and a negative net margin of 32.83%. The business had revenue of $48.07 million during the quarter, compared to the consensus estimate of $46.80 million. During the same quarter last year, the company earned ($0.14) EPS. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Trading Up 2.5 %

Shares of NASDAQ XERS opened at $3.34 on Thursday. The business has a 50-day moving average of $2.93 and a 200-day moving average of $2.47. The firm has a market capitalization of $497.66 million, a price-to-earnings ratio of -7.58 and a beta of 2.70. Xeris Biopharma has a 12 month low of $1.46 and a 12 month high of $3.39.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Xeris Biopharma in a report on Thursday, August 15th.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.